# Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

> **NCT03391869** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 339 (actual)

## Conditions studied

- Lung Adenocarcinoma
- Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** Ipilimumab
- **PROCEDURE:** Local Consolidation Therapy
- **BIOLOGICAL:** Nivolumab
- **OTHER:** Quality-of-Life Assessment
- **RADIATION:** Radiation Therapy
- **PROCEDURE:** Therapeutic Conventional Surgery

## Key facts

- **NCT ID:** NCT03391869
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-12-29
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 339 (ACTUAL)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03391869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03391869, "Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03391869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*